Артродарин - новый препарат для патогенетической терапии остеоартроза
https://doi.org/10.14412/1995-4484-2009-459
Аннотация
Остеоартроз (ОА) является одним из наиболее распространенных заболеваний опорно-двигательного аппарата, особенно у лиц старшей возрастной группы.С современных позиций ОА рассматривается как гетерогенная группа заболеваний, имеющих различную этиологию, но сходные биологические, морфологические и клинические черты.Патологический процесс при ОА затрагивает не только хрящ, но и субхондральную кость, связки, капсулу сустава, а также периартикулярные мышцы, синовиальную оболочку, в которой развивается основной воспалительный процесс, приводящий к нарушению структуры хряща, образованию вначале поверхностных его повреждений, а затем глубоких трещин, формированию остеофитов, нарушению конгруэнтности суставных поверхностей. Следствием этих процессов является боль, нарушение функции сустава, ухудшение качества жизни пациентов вплоть до потери трудоспособности и инвалидизации [1, 2]. Диагноз ОА, несмотря на технический прогресс и внедрение в медицинскую практику сонографии суставов, компьютерной томографии, магнитно-резонансной техники, часто ставится на поздних сроках болезни из-за отсутствия болевого синдрома, который является основной причиной обращаемости больного к врачу.
Список литературы
1. <div><p>Rogers R., Shepstone L., Dieppe F. Is osteoarthritis a systemic disorder? Arthritis Rheum., 2004, 50, 452-7</p><p>Dequeker I., Luyten F.P. The history of osteoarthritis-osteoarthrosis. Ann. Rheum. Dis., 2008, 67(1), 5-10</p><p>Алексеева Л.И. Остеоартроз. В кн. Ревматология. Нац. руководство. М., 2008, 573–89</p><p>Van de Loo F.A., Joosten L.A., van Lent P.L. et al. Role of interleukin-1, tumor necrosis factor alpha, and interleukin-6 in cartilage proteoglycan metabolism and destruction: effect of in situ blocking in murine antigen-and zymosan-induced arthritis. Arthritis Rheum., 1995, 38(2), 164-72</p><p>Pelletier J.P., Mineau F., Ranger P. et al. The increased synthesis of inducible nitric oxide Inhibits IL-1ra syntesis by human articular chondrocytes: possible role in osteoarthritis cartilage degradation. Osteoarthr. Cart., 1996, 4(1), 77-84</p><p>Martel-Pelletier J., Mineau F., Jolicoeur F.C. et al. In vitro effects of Diacerhein and Rhein on IL-1 and TNF-α system in human osteoarthritis synovium and chondrocytes. J. Rheumatol.,1998, 25, 753-62</p><p>Yaron M., Shirazi I., Yaron I. Anti- interleukin-1 effects of Diacerhein and Rhein in human osteoarthritis synovial tissue and cartilage cultures. Osteoarthr. Cart., 1999, 7(3), 272-80</p><p>Moldovan F., Jolicoeur F.C., Martel-Pelletier J. Diacerhein and Rhein reduce the ICE-induced Il-1β and IL-18 activation in human osteoarthritis cartilage. Osteoarthr. Cart., 2000, 8,186-96</p><p>Mendes A.F., Caramona M.M., de Carvalho A.P. et al. Diacerhein and Rhein prevent interleukin-1b-induced nuclear factor-kappa B activation by inhibiting the degradation of inhibitor kappa B-alfa. Pharmacol. Toxicol., 2002, 91, 22-8</p><p>MengsholL.A.,VincentiM.P.,CoonC.etal.Interleukin-1 induction of collagenase 3 (matrix metalloproteinase 13) gene expressions in chondrocytes requires p38, c-Jun N-terminal kinase, and nuclear factor-kappa B: Differential regulation of collagenase 1 and collagenase 3. Arthritis Rheum., 2000, 43(4), 801-11</p><p>Martin G., Bogdanowicz P., Domagala F. et al. Rhein inhibits interleukin-1b- induced activation of MEK/ ERK pathway and DNA binding of NF-kappa B and AP-1in chondrocytes cultured in hypoxia: potential mechanism for its disease-modifying effect in osteoar- thritis. Inflammation, 2003, 27(4), 233-46</p><p>Lin S., Li JJ, Fujii M., Hou D.X. Rhein inhibits TPA- induced activator protein-1 activation and cell trans- formation by blocking the JNK-dependent pathway. Int. J. Oncol., 2003, 22(4), 829-33</p><p>Lovanovic D.V., Mineau F., Notoya K. et al. Nitric oxide induced cell death in human osteoarthritis syn- oviocytes is mediated by tyrosine kinase activation and hydrogen peroxide and /or superoxide formation. J. Rheumatol., 2002, 29 (10), 2165-75</p><p>Murell G.A., Jang D., Williams R.J. Nitric oxide activates metalloprotease enzymes in osteoarthritis cartilage. Biochem. Biophys. Res. Commun., 1995, 2, 199-206</p><p>Pelletier J.P, Mineau F., Fernandes J.S. et al. Diacerhein and Rhein reduce the Il-1β stimulated inducible nitric oxide synthesis level and activity while stimulating cyclooxygenase-2 synthesis in human osteoarthritis chondrocytes. J. Rheumatol., 1998, 25, 2417-24</p><p>Pelletier J.P, Mineau F., Boileau C. et al. Diacerhein reduces the level of cartilage chondrocyte DNA fragmentation and death in experimental dog osteoarthritis cartilage at the same time that in inhibits caspase-3 and inducible nitric oxide synthase. Clin. Exp. Rheumatol., 2003, 21(2), 171-7</p><p>Boitin M., Redini F., Loyau G. et al. Effect of Diacerhein (ART 50) on matrix synthesis and collagenase secretion by cultured rabbit joint chondrocytes. Rev. Rheum. (Ed. Fr.), 1993, 60 (6 bis), 68S-76S</p><p>Cruz T.F., Tang J., Pronost S. et al. Mecanismes moleculairis impliques dans inhibition expression of collagenase Diacerhein. Rev. Prat. (Paris), 1996, 46 (suppl. 6), S15-S19</p><p>Dozin B., Malpeli M., Camardella l. et al. Response of young, aged and human osteoarthritis articular chondrocytes to inflammatory cytokines: molecular and cellular aspects. Matrix. Biol., 2002, 21(5), 449-59</p><p>Sanchez C., Mathy-Hartert M., Deberg M.A. et al. Effects of rhein on human articular chondrocytes in alginate beads. Biochem. Pharmacol., 2003, 65 (3), 377-88</p><p>Frude Saleh T.S., Batista Calixto J., Santos Mederios Y. Effects of anti-inflammatory drugs upon nitrate and myeloperoxidase levels in the mouse pleurisy induced by carrageenan. Peptides, 1999, 20, 949-56</p><p>Raimndi L., Banchelli Soldaini G., Buffoni F. Rhein and derivatives in vitro studies on their capacity to inhibit certain proteases. Pharm. Res. Comm., 1982, 14, 103-12</p><p>Del RossoM., Fibbi G., Magnelli L at al. Modulation of urokinase receptors on human synovial cells and osteoarthritic chondrocytes by diacetylrhein. Int. J. Tiss. Reac., 1990, 12(2), 91-100</p><p>Schungen R.N., Gianetti B.M., van de Leur E. et al. Effect of diacetylrhein on the phagocytosis of polymorphonuclear leucocytes and its influence on the biosynthesis of hyaluronate in synovial cells. Arzneim- Forsch/Drug Res., 1988, 38(1), 744-48</p><p>Tamura t., Shirai T., Kosaka N. et al. Pharmacological studies of Diacerhein in animal models of inflammation, arthritis and bone resorption. Eur. J. Pharm., 2002, 448(1), 81-7</p><p>Felisaz N., Boumediene K., Ghayor C. et al. Stimulating effect of Diacerhein on TGF-β1 and b2 expression in articular chondrocytes cultured with and without IL-1. Osteoarthr. Cart., 1999, 7, 255-64</p><p>Pelletier J.P, Dibattista J.A., Roughley P. et al. Cytocines and inflammation in cartilage degradation. Rheum. Dis. Clin. Norht. Am., 1993, 19, 548-68</p><p>Brandt K.D., Manthy-Hartert M., Deberg M.A. et al. Effect of diacetylrhein in an accelerated canine model of osteoarthritis. Osteoarthr. Cart., 1997, 5, 438-49</p><p>Mitheu P., IL-1. Son role, son dosage, ses difficultes dans osteoarthrosis. Resalt une etude pilote avec Diacerhein dans gonarthrosis. Rev. Prat., 1999, Supple 13, S15-18</p><p>Pelletier J.P, Yaron M., Haraoui B. Efficacy and safety of Diacerhein in osteoarthritis of the knee. Arthr. Rheum., 2000, 43(10), 2339-48</p><p>Nguyen M., Dougades M., Berdah L. et al. Diacerhein 53 in the treatment of hip osteoarthritis. Arthritis Rheum., 1994, 37(4), 529-36.</p><p>Lequesne M., Berdah L., Gurentes I. Efficacy and tol- erability of Diacerhein in the treatment of knee and hip osteoarthritis. Rev. Prat., 1998, 48 (suppl. 17), S31-5</p><p>Louthrenoo W., Nilganuwong S., Aksaranugraha S. et al. Efficacy and safety of Diacerhein in the treatment of painful osteoarthritis of the knee. A randomized, multicentre, double-blind, piroxicam-controlled, parallel-group, phase III study. Abstr. APLAR 2004, Jeju, Korea, P186</p><p>Tang F.L., Wu D.H., Lu Z.G. et al. Efficacy and safety of Diacerhein in the treatment of painful osteoarthritis of the knee. Abstract presented at APLAR 2004, Jeju, Korea, P185</p><p>Pavelka K., Olejarova M., Rovensky J. Randomized, placebo-controlled Study of Diacerhein in painful osteoarthritis of the knee- assessment of carry-over effect. Ann. Rheum Dis., 2005, 64 (suppl III), 483</p><p>Leeb B.F., Rintelen B. Systematic meta-analysis trials with Diacerhein in osteoarthritis. Osteoarthr. Cart., 2005, 13 (suppl A), S68</p><p>Dougades M., Nguen M., Berdah L et al. for the ECHODIAN Investigators Study Group. Evaluation of the structure-modifying effects of Diacerhein in hip osteoarthritis. ECHODIAN, a three-year, placebo- controlled trial. Arthritis Rheum., 2001, 44(11), 2539- 47</p></div><br />
Рецензия
Для цитирования:
Балабанова Р.М., Kaptaeva A.K. Артродарин - новый препарат для патогенетической терапии остеоартроза. Научно-практическая ревматология. 2009;47(2):49-53. https://doi.org/10.14412/1995-4484-2009-459
For citation:
Balabanova R.M., Kaptaeva A.K. Arthrodarin – a new drug for osteoarthritis pathogenetic therapy. Rheumatology Science and Practice. 2009;47(2):49-53. (In Russ.) https://doi.org/10.14412/1995-4484-2009-459
Просмотров:
1096
Послать статью по эл. почте 